CTOs on the Move

Osteal Therapeutics

www.ostealtx.com

 
Osteal Therapeutics is a privately-held, clinical-stage pharmaceutical company developing novel musculoskeletal therapeutics to treat orthopedic infections and their consequences.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.ostealtx.com
  • 4835 Lyndon B Johnson Freeway Suite 520
    Dallas, TX USA 75244
  • Phone: 469.809.2630

Executives

Name Title Contact Details

Funding

Osteal Therapeutics raised $30M on 03/08/2022

Similar Companies

Abraxis Oncology

Abraxis Oncology is a Bridgewater, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cedarburg Hauser Pharmaceuticals

Cedarburg Pharmaceuticals delivers unsurpassed value in the development and manufacturing of commercial and clinical APIs. We believe value is more than just price. Value means making your life simpler. Our process development, scale-up, commercial

Vireo Health

Vireo Health, Inc. a physician-led multi-state medical cannabis company, is committed to safely alleviating pain by providing patients with best-in-class cannabis products and compassionate care.

Lyra Therapeutics

Creating precisely tuned medicines so patients can breathe freely, we are pioneering a new therapeutic approach to treat debilitating ear, nose and throat diseases that impact the lives of millions of people. Lyra Therapeutics is a clinical-stage company pioneering a new therapeutic approach to treat debilitating ear, nose and throat (ENT) diseases that impact the lives of millions of people. Our goal is to transform the ENT treatment paradigm by providing effective front-line solutions for physicians and new treatment options for their patients. Lyra`s transmucosal therapeutic system, now being evaluated in a clinical study, directly targets tissues that are difficult or impossible to access with existing therapies. Building on expertise in materials science, drug development and formulation, the Lyra team has developed a proprietary platform that enables sustained, local delivery of medications over an extended period of time. Based on clinical results, this new therapeutic approach has the potential to provide significantly improved patient outcomes beyond the limited treatment and surgical options currently available for ENT diseases. Headquartered in the Boston area, Lyra Therapeutics was founded by George Whitesides and Robert Langer, academic luminaries in the fields of chemistry, materials science and biotechnology, and is backed by leading life science investors.